Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Subject with CTEPH (WHO Group 4) judged as inoperable due to the localization of the obstruction being surgically inaccessible (i.e., distal disease).~* Female of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception.~Exclusion Criteria:~* Previous pulmonary endarterectomy.~* Recurrent thromboembolism despite sufficient oral anticoagulants.~* Symptomatic acute pulmonary embolism in the 6-month period prior to randomization.~* Known moderate-to-severe restrictive lung disease (i.e., TLC \< 60% of predicted value) or obstructive lung disease (i.e., FEV1 \< 70% of predicted, with FEV1/FVC \< 65%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema).~* Acute or chronic conditions (other than dyspnea) that limit the ability to comply with study requirements in the 3-month period prior to Screening visit or during the Screening period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan 10 mg, oral tablet, to be taken once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo oral tablet, to be taken once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).